AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 36201995
Drug: Cognitive Behavioral
RxNorm normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive Behavioral Therapy (CBT) for GAD
Trial: 32831984
Drug: Preoperative intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Preoperative intravenous infusion of 5 mg zoledronic acid (ZOL)
Trial: 36172051
Drug: Phenylephrine (0.54
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Phenylephrine (0.54 μg/kg/min)
Trial: 36172051
Drug: Norepinephrine (0.08
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Norepinephrine (0.08 μg/kg/min)
Trial: 36172051
Drug: Metaraminol (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metaraminol (2 μg/kg/min)
Trial: 35997325
Drug: Favipiravir (FPV)
RxNorm normalized name: favipiravir
DrugBank: Favipiravir (DB12466)
FDA approved: no
EMA approved: no
PMDA approved: yes
Description: Favipiravir (FPV) 1800 mg BID on Day 1 and 800 mg BID for 5-14 days thereafter
Trial: 32111892
Drug: Surgical treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Surgical treatment (PPV)
Trial: 32111892
Drug: IVB injections
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IVB injections
Trial: 32631958
Drug: Fan therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fan therapy (table fan)
Trial: 32631958
Drug: Fan therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fan therapy
Trial: 34958382
Drug: 3 doses
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 3 doses of 5 μg or 10 μg of a SARS-CoV-2 inactivated vaccine
Trial: 34887772
Drug: Moderate-intensity statin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Moderate-intensity statin therapy
Trial: 34262261
Drug: 2.5 mg
RxNorm normalized name: biotin 2.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2.5 mg frovatriptan succinate tablet (single-dose)
Trial: 34262261
Drug: 5 mg
RxNorm normalized name: talc 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg frovatriptan succinate tablet (single-dose)
Trial: 34262261
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg frovatriptan succinate tablet (single-dose)
Trial: 34262261
Drug: 2.5 mg
RxNorm normalized name: biotin 2.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2.5 mg frovatriptan succinate tablet (multiple-dose, 12 times in 7 days)
Trial: 34411221
Drug: DAS (implants
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DAS (implants with surface modified by double acid‐etching and sandblasting)
Trial: 34411221
Drug: DAS-H (implants
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DAS-H (implants with surface modified by double acid‐etching and sandblasting, stored in 0.9% saline solution)
Trial: 35381390
Drug: Levothyroxine (LT4)
RxNorm normalized name: LT4
DrugBank: Levothyroxine (DB00451)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Levothyroxine (LT4) therapy
Trial: 35107429
Drug: Enhanced care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enhanced care (EC) with continuous glucose monitoring and low-carbohydrate nutrition counseling (<100 g/day)
Trial: 35699263
Drug: Therapy Program
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Therapy Program for Management of Chronic Cough (TMCC)
Trial: 36397102
Drug: Pharmacist-led medication
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmacist-led medication review, patient counselling, and information transmission to general practitioners and community pharmacies after discharge
Trial: 35986297
Drug: Donepezil (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Donepezil (5 mg/day)
Trial: 36074747
Drug: Copper oxide
RxNorm normalized name: Copper oxide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Copper oxide wire particles (COWP) 2 g administered orally
Trial: 36074747
Drug: Placebo control
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo control capsule
Trial: 34791074
Drug: Fosfomycin (3g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fosfomycin (3g once daily for 10 days)
Trial: 34791074
Drug: Ciprofloxacin (0.5g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ciprofloxacin (0.5g twice daily for 10 days)
Trial: 32711957
Drug: L +
RxNorm normalized name: Citracal + D
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L + ICE (ice slurry ingestion)
Trial: 32711957
Drug: L +
RxNorm normalized name: Citracal + D
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L + AMB (ambient water ingestion)
Trial: 33811761
Drug: Velusetrag 5
RxNorm normalized name: Velusetrag
DrugBank: Velusetrag (DB12702)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Velusetrag 5 mg
Trial: 35265302
Drug: Low-Level Laser
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-Level Laser Therapy (LLLT) combined with conventional physical therapy
Trial: 39775073
Drug: Conventional physical
RxNorm normalized name: hypochlorite
DrugBank: Hypochlorite (DB11123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional physical therapy alone
Trial: 32299355
Drug: LPS (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LPS (10 μg/ml)
Trial: 32299355
Drug: Poly (I:C)
RxNorm normalized name: C.I. acid blue 324
DrugBank: Poly(lactic acid) (DB15037)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Poly (I:C) (10 μg/ml)
Trial: 32299355
Drug: Heat-inactivated Vibrio
RxNorm normalized name: INFLUENZA A VIRUS A/SINGAPORE/6/86 (H1N1) ANTIGEN (HEAT INACTIVATED)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Heat-inactivated Vibrio harveyi (107 cell/ml)
Trial: 32299355
Drug: LPS dose-increased
RxNorm normalized name: LP-20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LPS dose-increased treatment (0, 10, 20, and 50 μg/ml)
Trial: 32129194
Drug: Alpha-keto analogue
RxNorm normalized name: Keto-C
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alpha-keto analogue (600 mg tablet three times a day)
Trial: 32129194
Drug: Alpha-keto analogue
RxNorm normalized name: Keto-C
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alpha-keto analogue (600 mg tablet three times a day) + Nigella sativa oil (2.5 mL, per orally, once daily) for 12 weeks
Trial: 34755007
Drug: Monthly minodronate
RxNorm normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Monthly minodronate (MIN group)
Trial: 33324264
Drug: Vignette 2
RxNorm normalized name: Ultra Violette Mini Mates Duo Pack KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vignette 2 (patient receiving amlodipine treatment)
Trial: 32715744
Drug: Pulsed ultrasound
RxNorm normalized name: ULTRASOUND
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pulsed ultrasound treatment
Trial: 38580558
Drug: Direct Oral
RxNorm normalized name: direct blue 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Direct Oral Anticoagulants (DOAC)
Trial: 34498307
Drug: Pomegranate extract
RxNorm normalized name: Pomegranate Extract
DrugBank: Pomegranate (DB14317)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pomegranate extract tablets
Trial: 32674447
Drug: Topical dexamethasone
RxNorm normalized name: dexamethasone Topical Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical dexamethasone
Trial: 35931103
Drug: IMGX003 (1200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IMGX003 (1200 mg)
Trial: 32748473
Drug: Silymarin (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Silymarin (40 g/day)
Trial: 35918106
Drug: Daprodustat three
RxNorm normalized name: daprodustat
DrugBank: Daprodustat (DB11682)
FDA approved: no
EMA approved: no
PMDA approved: yes
Description: Daprodustat three times weekly
Trial: 33125769
Drug: Observation without
RxNorm normalized name: threonine
DrugBank: Threonine (DB00156)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Observation without treatment (OBS)
Trial: 32114186
Drug: Minimal treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Minimal treatment
Trial: 34036760
Drug: Abdominal massage
RxNorm normalized name: PAD,ABDOMINAL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Abdominal massage (I Love You method), 15 minutes before feeding, twice a day for 5 days
Trial: 33549600
Drug: Oral information
RxNorm normalized name: Inflammation OTC Bruise
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral information plus an information pamphlet (Group 1; n = 45)
Trial: 33549600
Drug: Oral information
RxNorm normalized name: Inflammation OTC Bruise
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral information alone (Group 2; n = 45)
Trial: 35787693
Drug: Solutech (10.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Solutech (10.0 mg Δ9‐THC, 9.76 mg CBD)
Trial: 35787693
Drug: MCT-oil (10.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MCT-oil (10.0 mg Δ9‐THC, 9.92 mg CBD)
Trial: 33502237
Drug: Intense neoadjuvant
RxNorm normalized name: Uricalm Intensive
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intense neoadjuvant androgen deprivation therapy followed by radical prostatectomy
Trial: 33502237
Drug: Testosterone recovery
RxNorm normalized name: Testosterone
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Testosterone recovery post-treatment
Trial: 33189627
Drug: Lisinopril (in
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lisinopril (in participants with diabetes)
Trial: 33189627
Drug: Lisinopril (in
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lisinopril (in diabetes-free participants)
Trial: 33462940
Drug: Conventional pharmacological
RxNorm normalized name: COPD pharmacologic substance
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional pharmacological treatment (Essentiale plus Yasmin)
Trial: 32744056
Drug: Continuation of
RxNorm normalized name: varenicline
DrugBank: Varenicline (DB01273)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Continuation of aspirin therapy during the perioperative period (33 eyes)
Trial: 32744056
Drug: Discontinuation of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Discontinuation of aspirin therapy for 3 to 7 days before surgery (34 eyes)
Trial: 32744056
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group with no antiplatelet/anticoagulant therapy (43 eyes)
Trial: 35109491
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of GMT and RCS
Trial: 36280113
Drug: Dapagliflozin treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dapagliflozin treatment for 5 weeks
Trial: 32562450
Drug: Smectite at
RxNorm normalized name: rose bengal AT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Smectite at 0.5 g/kg PO per day divided in two to three doses
Trial: 32562450
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group without initial medication
Trial: 35834790
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy (nivolumab + ipilimumab)
Trial: 34416347
Drug: Semi-active control
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Semi-active control treatment (electromyogram biofeedback)
Trial: 34416347
Drug: SCP-NF and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SCP-NF and Semi-active control treatment
Trial: 35708431
Drug: TAP (triple
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TAP (triple antibiotic paste)
Trial: 34851731
Drug: Providing children
RxNorm normalized name: Pediaclear Childrens
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Providing children with >60 minutes of outdoor play daily
Trial: 34953603
Drug: Standard treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard treatment of 77 Gy to the entire prostate in 35 fractions
Trial: 34099307
Drug: TAU arm
RxNorm normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: TAU arm (treatment-as-usual, testing results not available until 8-week visit, n = 92)
Trial: 35961356
Drug: Typhoid conjugate
RxNorm normalized name: Typhoid conjugate vaccine (TCV)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Typhoid conjugate vaccine (TCV)
Trial: 35961356
Drug: Meningococcal serogroup
RxNorm normalized name: MENINGOCOCCAL B
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Meningococcal serogroup A conjugate vaccine (MCV-A)
Trial: 32333539
Drug: Medication (Diclofenac
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medication (Diclofenac Sodium and Mecobalamine)
Trial: 35551290
Drug: Empagliflozin 25
RxNorm normalized name: empagliflozin 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Empagliflozin 25 mg d−1 with closed-loop therapy
Trial: 35551290
Drug: Empagliflozin 25
RxNorm normalized name: empagliflozin 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Empagliflozin 25 mg d−1 with sensor-augmented pump (SAP) therapy
Trial: 35551290
Drug: Closed-loop therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Closed-loop therapy plus empagliflozin
Trial: 35551290
Drug: Placebo with
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo with closed-loop therapy
Trial: 35551290
Drug: Placebo with
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo with SAP therapy
Trial: 33914770
Drug: Trusting peer
RxNorm normalized name: Polar Frost
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trusting peer educators for HIV treatment
Trial: 36027483
Drug: Vinorelbine/Cisplatin (Chemotherapy)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vinorelbine/Cisplatin (Chemotherapy)
Trial: 33105928
Drug: Yimitasvir phosphate
RxNorm normalized name: Yimitasvir
DrugBank: Yimitasvir (DB18768)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Yimitasvir phosphate capsules with sofosbuvir tablets
Trial: 33105928
Drug: Yimitasvir phosphate
RxNorm normalized name: Yimitasvir
DrugBank: Yimitasvir (DB18768)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Yimitasvir phosphate capsules with omeprazole magnesium enteric-coated tablets
Trial: 33105928
Drug: Yimitasvir phosphate
RxNorm normalized name: Yimitasvir
DrugBank: Yimitasvir (DB18768)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Yimitasvir phosphate capsules with rosuvastatin calcium tablets
Trial: 35294067
Drug: Insulin resistance
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Insulin resistance (IR) defined by HOMA-IR >2.5
Trial: 35294067
Drug: Non-insulin resistance
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Non-insulin resistance (non-IR)
Trial: 32557001
Drug: Fractional CO2
RxNorm normalized name: LIVER FRACTION
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fractional CO2 laser therapy with 50 units of BTX-A solution applied topically post-operatively
Trial: 86263812
Drug: Branched chain
RxNorm normalized name: Branched Chain Amino Acids
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Branched chain amino acids (0.25 g/kg/day)
Trial: 86263812
Drug: Casein (0.25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Casein (0.25 g/kg/day)
Trial: 32317241
Drug: Machine learning-based
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Machine learning-based treatment planning system (PIPA system)
Trial: 32317241
Drug: Conventional, manual
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional, manual treatment planning technique
Trial: 35474582
Drug: Sublingual 300
RxNorm normalized name: Oralair 300 Sublingual Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sublingual 300 IR HDM tablets
Trial: 36033243
Drug: Systemic heparin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Systemic heparin anticoagulation for CRRT
Trial: 36134707
Drug: Prediction model
RxNorm normalized name: reductic acid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prediction model developed using clinical and drug-related variables from training data set.
Trial: 32519599
Drug: Regular low-dose
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Regular low-dose sustained-release morphine (8-32 mg/24 h)
Trial: 35275529
Drug: DHP1401 500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DHP1401 500 mg
Trial: 35275529
Drug: DHP1401 1000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DHP1401 1000 mg
Trial: 35275529
Drug: DHP1401 500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DHP1401 500 mg and Donepezil 5 mg
Trial: 33567928
Drug: Antiviral drug
RxNorm normalized name: antiviral drugs
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antiviral drug (oseltamivir) alone
Trial: 32107956
Drug: Serum miR‐125b
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Serum miR‐125b in combination with serum CA125
Trial: 36253766
Drug: Tele-delivered problem-solving
RxNorm normalized name: DELIVER
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tele-delivered problem-solving therapy (Tele-PST)
Trial: 33449527
Drug: Cellex (0.1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cellex (0.1 mg daily SC for 10 days)
Trial: 33449527
Drug: Cortexin (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cortexin (10 mg per 2 ml of 0.9% NaCl solution IM daily for 10 days)
Trial: 33587381
Drug: DaxibotulinumtoxinA for
RxNorm normalized name: daxibotulinumtoxinA-lanm
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DaxibotulinumtoxinA for Injection (DAXI)
Trial: 33029812
Drug: PDS with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PDS with calcium concentration of 1.75 mmol/L (high concentration group)
Trial: 33029812
Drug: PDS with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PDS with calcium concentration of 1.25 mmol/L (low concentration group)
Trial: 32928500
Drug: Antipsychotic-naïve patients
RxNorm normalized name: patent blue violet
DrugBank: Patent Blue (DB13967)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antipsychotic-naïve patients
Trial: 39326506
Drug: Stereotactic body
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Stereotactic body radiation therapy (SBRT)
Trial: 33735217
Drug: Less invasive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Less invasive treatments
Trial: 33084149
Drug: Empagliflozin 10
RxNorm normalized name: empagliflozin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Empagliflozin 10 mg and 25 mg
Trial: 35471469
Drug: 15 mg/day
RxNorm normalized name: Climara Pro 0.045/0.015 MG/Day Weekly Transdermal System
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 15 mg/day tolvaptan (TLV) plus original FUR dose for 7 days
Trial: 35471469
Drug: 120–200 mg/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 120–200 mg/day furosemide (FUR) for 7 days
Trial: 34187185
Drug: Liraglutide (1.8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Liraglutide (1.8 mg once daily for 26 weeks)
Trial: 34187185
Drug: Placebo (once
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (once daily for 26 weeks)
Trial: 34148643
Drug: Multimodal protocol
RxNorm normalized name: Olay Professional Acne Protocol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multimodal protocol combining a motivational interview, subcutaneous injection of NicoSan®, and hyperhydration.
Trial: 35590388
Drug: 1% topical
RxNorm normalized name: SSD 1% Topical Cream
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1% topical diclofenac gel
Trial: 34480575
Drug: SCB-2019 vaccine
RxNorm normalized name: influenza A virus (H1N1) antigen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SCB-2019 vaccine (3, 9, or 30 µg doses)
Trial: 35742477
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (information related to daily recommended PA levels)
Trial: 36478528
Drug: Follitropin delta
RxNorm normalized name: follitropin delta
DrugBank: Follitropin (DB00066)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Follitropin delta 12 μg
Trial: 36478528
Drug: Follitropin delta
RxNorm normalized name: follitropin delta
DrugBank: Follitropin (DB00066)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Follitropin delta 18 μg
Trial: 36478528
Drug: Follitropin delta
RxNorm normalized name: follitropin delta
DrugBank: Follitropin (DB00066)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Follitropin delta 24 μg
Trial: 36478528
Drug: Follitropin delta
RxNorm normalized name: follitropin delta
DrugBank: Follitropin (DB00066)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Follitropin delta (all doses)
Trial: 33799044
Drug: CORT (20mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CORT (20mg oral cortisol)
Trial: 33242083
Drug: 3-week antibiotic
RxNorm normalized name: etonogestrel
DrugBank: Etonogestrel (DB00294)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 3-week antibiotic therapy
Trial: 33242083
Drug: 6-week antibiotic
RxNorm normalized name: perampanel
DrugBank: Perampanel (DB08883)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 6-week antibiotic therapy
Trial: 32618207
Drug: Multimodal therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multimodal therapy (MT)
Trial: 37682792
Drug: Zanubrutinib (160
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zanubrutinib (160 mg twice daily)
Trial: 33992421
Drug: Intramuscular progesterone
RxNorm normalized name: Progesterone
DrugBank: Progesterone (DB00396)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intramuscular progesterone (50 mg daily)